ConCallIQ
Go Pro
Home › Dr. Reddy's Laboratories › Revenue History

Dr. Reddy's Laboratories Revenue History — Quarter by Quarter

Dr. Reddy's Laboratories's revenue moved from ₹6,738 Cr in Q1 FY24 to ₹7,546 Cr in Q4 FY26, a 12.0% change over 12 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q4 FY26₹7,546 Cr-6%
Q3 FY26₹8,753 Cr+4.4%
Q2 FY26₹8,828 Cr+9.8%
Q1 FY26₹8,545 Cr+11%
Q4 FY25₹8,506 Cr+20%
Q3 FY25₹8,359 Cr+16%
Q2 FY25₹8,038 Cr+17%
Q1 FY25₹7,673 Cr+14%
Q4 FY24₹7,083 Cr+12%
Q3 FY24₹7,215 Cr+7%
Q2 FY24₹6,880 Cr+9%
Q1 FY24₹6,738 Cr+29%

What management said about revenue

G

Q4 FY26 · FY27 EBITDA margin near 25% with semaglutide

EBITDA margin is expected to approach 25% in FY27, aided by semaglutide sales, though may be slightly below.

G

Q4 FY26 · FY27 R&D spend 7%-8% of revenue

R&D expenditure is expected to be in the range of 7%-8% of adjusted revenue in FY27.

G

Q3 FY26 · Semaglutide launch in India on March 21, 2026

Dr. Reddy's will launch generic Ozempic (diabetes) in India on March 21, with all strengths including oral Rybelsus.

G

Q3 FY26 · Canada Semaglutide approval expected by May 2026

Health Canada response expected between end-February and May 2026, with launch preparation underway for Q4 or Q1.

G

Q3 FY26 · Abatacept U.S. launch expected end of calendar 2026

IV presentation BLA filed December 2025; approval expected around end-2026, with sub-Q filing in July 2026 and launch by Jan/Feb 2028.

G

Q2 FY26 · EBITDA margin to return to 25%+ in two years

Management maintains commitment to achieving 25%+ EBITDA margins within the next two years, driven by cost efficiencies and pipeline growth.

G

Q2 FY26 · Abatacept BLA submission by end of December 2025

BLA for abatacept IV will be submitted by end of calendar 2025, with high confidence in approval.

G

Q2 FY26 · Semaglutide launch in 87 countries within 12-15 months

Expects to obtain approval in 87 countries and launch 12 million pens, with Canada as a key market.

G

Q1 FY26 · Semaglutide launch in Canada by early 2026

Expects approval between end-Oct and early-Nov 2025, with launch at LOE in Jan 2026, subject to IP clearance and approval.

G

Q1 FY26 · R&D spend 7%-7.5% of sales for FY26

R&D investments expected in this range for the full fiscal year.

G

Q4 FY25 · Double-digit revenue growth in FY26

Management expects double-digit revenue growth for FY2026, including contributions from new launches and biosimilars, despite REVLIMID exclusivity ending in January 2026.

G

Q4 FY25 · EBITDA margin maintained at ~28% in FY26

Management guided for EBITDA margins to remain around 28% in FY2026, similar to FY2025 levels, through productivity measures and revenue growth.